INTRODUCTION. The analgesic/sedative therapy is necessary notwithstanding presents important side effects. Critically ill frequently present alterations of the circadian rhythm, delirium and agitation episodes with the risk of receiving additional sedation. The dramatically reduced endogenous blood melatonin level (both in the basal levels and in night peaks) could play a role in this context. OBJECTIVES. Reducing the need for sedatives and analgesic drugs by the oral administration of melatonin in high-risk critically ill [1] treated with conscious sedation [2]. METHODS. Double-blind RCT between placebo and Melatonin (3 9 2 mg), administered daily at 8 and 12 p.m. from the third ICU day until discharge. Inclusion criteria: ageC18 years, SAPSII[32 points, expected mechanical ventilation (MV) C4, practicability of gastroenteric tract. All patients were treated according to the local guidelines: propofol or midazolam during the first 48 h, immediate introduction of enteral sedation with hydroxyzine (until 600 mg/die) and supplementary lorazepam (until 16 mg/die) if necessary. Therapy was titrated at least three times a day, in order to obtain a conscious sedation (RASS = 0) as soon as possible. RESULTS. 96 patients enrolled: age 72 [60–77] years, SAPS II 41 [34–54] points,MV11 [6– 22] days. Diagnosis: 17 pancreatitis, 37 acute lung diseases, 23 acute heart diseases, 19 other. The analgesic/sedative therapy during the first 3 ICU days (clinical stabilization) was not different between groups. Melatonin administration determined: early weaning from sedatives and analgesics (Fig. 1; p = 0.0005); significant decrease in total administered doses of hydroxyzine: 2,700 (100–8,050) versus 300 (0–2100), p.001; BDZP equivalents: 1 (0– 105) versus 0 (0–8), p.001; haloperidol: 0 (0–15.9) versus 0 (0–3), p.001; propofol: 20 (0–980) versus 0 (0–40), p.001; opiates: 2.5 (0–82.5) versus 0 (0–20), p.001; decrease of pain events (VNR[3): 28.6 versus 23.7%, p.001; anxiety (VNR[3): 34.3 versus 29.8%, p.001; agitation (longer than 1 h): 34.3 versus 32.2%, p.001; decrease in physical restraints use: 41.8 versus 31.1%, p.001; higher RASS: 0 [-1–0] versus 0 [0–0], p = 0.003.

Oral melatonin decreases need for sedatives and analgesics in critically ill / G. Mistraletti, B. Cerri, S. Miori, G. Sabbatini, I. Galluccio, M. Umbrello, R. Fiameni, S. Salini, A. Morabito, F. Fraschini, G. Iapichino. - In: INTENSIVE CARE MEDICINE. - ISSN 0342-4642. - 37:Suppl. 1(2011 Sep), pp. S181-S181. ((Intervento presentato al 24. convegno Annual Congress of the European Society of Intensive Care Medicine (ESICM) tenutosi a Berlin nel 2011.

Oral melatonin decreases need for sedatives and analgesics in critically ill

G. Mistraletti
Primo
;
S. Miori;G. Sabbatini;M. Umbrello;R. Fiameni;S. Salini;A. Morabito;G. Iapichino
Ultimo
2011

Abstract

INTRODUCTION. The analgesic/sedative therapy is necessary notwithstanding presents important side effects. Critically ill frequently present alterations of the circadian rhythm, delirium and agitation episodes with the risk of receiving additional sedation. The dramatically reduced endogenous blood melatonin level (both in the basal levels and in night peaks) could play a role in this context. OBJECTIVES. Reducing the need for sedatives and analgesic drugs by the oral administration of melatonin in high-risk critically ill [1] treated with conscious sedation [2]. METHODS. Double-blind RCT between placebo and Melatonin (3 9 2 mg), administered daily at 8 and 12 p.m. from the third ICU day until discharge. Inclusion criteria: ageC18 years, SAPSII[32 points, expected mechanical ventilation (MV) C4, practicability of gastroenteric tract. All patients were treated according to the local guidelines: propofol or midazolam during the first 48 h, immediate introduction of enteral sedation with hydroxyzine (until 600 mg/die) and supplementary lorazepam (until 16 mg/die) if necessary. Therapy was titrated at least three times a day, in order to obtain a conscious sedation (RASS = 0) as soon as possible. RESULTS. 96 patients enrolled: age 72 [60–77] years, SAPS II 41 [34–54] points,MV11 [6– 22] days. Diagnosis: 17 pancreatitis, 37 acute lung diseases, 23 acute heart diseases, 19 other. The analgesic/sedative therapy during the first 3 ICU days (clinical stabilization) was not different between groups. Melatonin administration determined: early weaning from sedatives and analgesics (Fig. 1; p = 0.0005); significant decrease in total administered doses of hydroxyzine: 2,700 (100–8,050) versus 300 (0–2100), p.001; BDZP equivalents: 1 (0– 105) versus 0 (0–8), p.001; haloperidol: 0 (0–15.9) versus 0 (0–3), p.001; propofol: 20 (0–980) versus 0 (0–40), p.001; opiates: 2.5 (0–82.5) versus 0 (0–20), p.001; decrease of pain events (VNR[3): 28.6 versus 23.7%, p.001; anxiety (VNR[3): 34.3 versus 29.8%, p.001; agitation (longer than 1 h): 34.3 versus 32.2%, p.001; decrease in physical restraints use: 41.8 versus 31.1%, p.001; higher RASS: 0 [-1–0] versus 0 [0–0], p = 0.003.
Settore MED/41 - Anestesiologia
Settore SECS-S/01 - Statistica
Settore MED/01 - Statistica Medica
set-2011
European Society of Intensive Care Medicine (ESICM)
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/165248
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact